World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
86
Citations
31007
World Ranking
14002
National Ranking
7106

Carmen J. Allegra publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Carmen J. Allegra sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 399 publications — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Carmen J. Allegra D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Carmen J. Allegra sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Carmen J. Allegra is affiliated with the University of Florida in the United States and has contributed extensively to the field of medicine, with a focus on oncology. Their research encompasses a range of subfields, including oncology, cancer research, pulmonary and respiratory medicine, pathology and forensic medicine, and surgery.

The scientist's work covers several main topics within cancer studies, particularly concentrating on colorectal cancer. These topics include colorectal cancer treatments and studies, cancer genomics and diagnostics, genetic factors in colorectal cancer, pancreatic and hepatic oncology research, cancer immunotherapy and biomarkers, colorectal cancer surgical treatments, and PARP inhibition in cancer therapy.

Among their recent published papers are:

  • Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406), 2020, Journal of Clinical Oncology
  • ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper, 2020, Nature Reviews Clinical Oncology
  • Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials, 2020, Journal of Clinical Oncology
  • Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34,640 Patients in the ACCENT Database, 2020, JNCI Journal of the National Cancer Institute
  • BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers, 2022, Journal of Hematology & Oncology

The scientist has collaborated frequently with several coauthors, including Thomas J. George, Norman Wolmark, Ji-Hyun Lee, Greg Yothers, and David L. DeRemer. Their publication record shows considerable involvement with leading venues in the field such as the Journal of Clinical Oncology, UNC Libraries, Cancer Research, JNCI Journal of the National Cancer Institute, and Breast Cancer Research.

The largest number of publications are in the Journal of Clinical Oncology, indicating a strong emphasis on clinical cancer research related to oncology. This aligns with their primary research areas and their contributions to both clinical trials and cancer genomics.

Best Publications

  • American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

    Carmen J. Allegra;Carmen J. Allegra;J. Milburn Jessup;Mark R. Somerfield;Stanley R. Hamilton

  • Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

    Eric Van Cutsem;Josep Tabernero;Radek Lakomy;Hans Prenen

  • Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03

    Mark S. Roh;Linda H. Colangelo;Michael J. O'Connell;Greg Yothers

  • Thymidylate Synthase Gene and Protein Expression Correlate and Are Associated with Response to 5-Fluorouracil in Human Colorectal and Gastric Tumors

    Patrick G. Johnston;Heinz-Josef Lenz;Cynthia G. Leichman;Kathleen D. Danenberg

  • Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses

    Greg Yothers;Michael J. O'Connell;Carmen J. Allegra;J. Philip Kuebler

  • Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

    Carmen J. Allegra;Greg Yothers;Michael J. O'Connell;Saima Sharif

  • Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials

    Daniel J. Sargent;Barbara A. Conley;Carmen Allegra;Laurence Collette

  • Polyglutamation of methotrexate. Is methotrexate a prodrug

    B A Chabner;C J Allegra;G A Curt;N J Clendeninn

  • The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer.

    P G Johnston;E R Fisher;H E Rockette;B Fisher

  • DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy

    Frank A. Sinicrope;Nathan R. Foster;Stephen N. Thibodeau;Silvia Marsoni

  • Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04

    Michael J. O'Connell;Linda H. Colangelo;Robert W. Beart;Nicholas J. Petrelli

  • Prognostic and Predictive Roles of High-Degree Microsatellite Instability in Colon Cancer: A National Cancer Institute–National Surgical Adjuvant Breast and Bowel Project Collaborative Study

    George P. Kim;Linda H. Colangelo;H. Samuel Wieand;Soonmyung Paik

  • Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates.

    Carmen J. Allegra;James C. Drake;Jacques Jolivet;Bruce A. Chabner

  • Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)

    Scott Kopetz;Katherine A. Guthrie;Van K. Morris;Heinz Josef Lenz

  • Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes’ B and C Colon Cancer: A National Cancer Institute–National Surgical Adjuvant Breast and Bowel Project Collaborative Study

    Carmen J. Allegra;Soon Paik;Linda H. Colangelo;Allyson L. Parr

  • Molecular biomarkers for the evaluation of colorectal cancer: Guideline from The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology

    Antonia R. Sepulveda;Antonia R. Sepulveda;Stanley R. Hamilton;Carmen J. Allegra;Wayne Grody

  • Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer.

    S M Swain;M E Lippman;E F Egan;J C Drake

  • National Institutes of Health State-of-the-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22–24, 2009

    Carmen J. Allegra;Denise R. Aberle;Pamela Ganschow;Stephen M. Hahn

  • Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer

    Carmen J. Allegra;Greg Yothers;Michael J. O'Connell;Saima Sharif

  • Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines.

    Patrick G. Johnston;James C. Drake;Jane Trepel;Carmen J. Allegra

Frequent Co-Authors

Bruce A. Chabner
Bruce A. Chabner Harvard University
Norman Wolmark
Norman Wolmark University of Pittsburgh
Patrick G. Johnston
Patrick G. Johnston Queen's University Belfast
Richard M. Goldberg
Richard M. Goldberg West Virginia University
Seth M. Steinberg
Seth M. Steinberg National Institutes of Health
Soonmyung Paik
Soonmyung Paik Yonsei University
Henry Masur
Henry Masur National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in healthcare doesn’t always mean following the traditional medical school route. There are several flexible and accelerated online programs tailored for professionals looking to advance or shift their careers. For registered nurses, rn to bsn programs no clinicals offer a convenient way to earn a Bachelor of Science in Nursing without the need for in-person clinical hours, making it ideal for working nurses.

Those aiming for advanced practice roles might consider a 1 year dnp program online, which enables experienced nurses to reach the highest educational level in a shorter timespan. In addition, the easiest dnp program online options can help minimize the academic and time-intensive barriers while still providing a rigorous education.

For those starting out, fastest lpn program formats empower new entrants to the healthcare workforce by offering quick, accredited pathways to become a Licensed Practical Nurse. Each of these online options allows for flexibility and fast-tracked learning, supporting a wide range of career goals within healthcare.

Best Scientists Citing Carmen J. Allegra

Trending Scientists

Recently Published Articles